

# Flow cytometric characterization of the tumor-infiltrating immune compartment: Significant differences in the tumor immune repertoire versus peripheral blood

Nandini Pal Basak<sup>1\*</sup>, Shivani Vignesh<sup>1</sup>, Sampratha Bhagyashekar<sup>1</sup>, Manimaran Manickam<sup>1</sup>, Debika Datta<sup>1</sup>, Anupam Nath<sup>1</sup>, Misti Jain<sup>1</sup> and Jason Wall<sup>2\*</sup>

<sup>1</sup>Farcast Biosciences India Pvt. Ltd., India, <sup>2</sup>Farcast Biosciences Inc, USA

## Abstract:

Characterization of the tumor microenvironment (TME) is expected to be critical in informing prognosis and guiding response prediction<sup>1,2</sup>. Recent studies have classified the TME based on tumor infiltrating leukocytes (TILs), programmed death-ligand 1 (PDL1) expression, and the nature of inflammatory responses<sup>1,3</sup>. Tumor studies involving transcript profiling and IHC have begun to inform the diversity and complexity of the tumor-infiltrated immune compartment (TIIC) by defining aspects of cellular composition, spatial distribution, and function. The use of flow cytometry allows the elucidation of an array of immune cell subtypes across entire samples. This study characterizes immune cell population subsets and tumor cells in four cancer types (breast, head and neck, colorectal, and gall bladder) from patients using multi-color flow cytometry. A good correlation was observed ( $r = 0.89, p = 0.003$ ) between tumor content, as evaluated by a pathologist (Hematoxylin and Eosin staining), and tumor content (EpCAM/panCK[7/8]+ cells) as estimated by flow cytometry (for all cancers excepting head and neck). Using pathology scoring we divided the samples into high-content (>10% tumor) and low-content (<10% tumor) samples. Samples with high tumor content were further examined by comparing the immune population in the tissue with their matched peripheral blood mononuclear cells (PBMC). We observed significantly higher proportions of T-cells, T-regulatory cells (Tregs) and exhausted T-cells (PD-1+ T-cells) in TIIC in comparison to its matched PBMC, while a lower proportion of B-cells and NK cells was noted. Also, samples with high tumor content had a significantly increased proportion of CD8 T-cells, Tregs and NK cells and a lower proportion of effector CD4 (CD4+Foxp3-) T-cells in comparison to the samples with low tumor content. The results from this study demonstrate the differences in the peripheral immune repertoire from the TIIC, reaffirming the need to robustly characterize the local TME. Additionally, the similarity in Treg and exhausted T-cell profiles across the indications examined may support a broad utility for therapeutics that can successfully target immune exhaustion or suppression.


## Methodology:

**PBMC isolation:** Blood was collected in ACD tubes (#02-684-26, BD) prior to surgery and transferred at 4°C. PBMCs were isolated using Histopaque 1077 (#10771, Sigma) by layering 4ml of blood over 4ml of Histopaque 1077 at room temperature. It was centrifuged at 700g for 20 minutes with break setting at acc 9/ dec 5. The layer in the interface was pipetted out into a separate tube and washed with PBS.

**Tissue dissociation:** The tissue samples (small fragments ~2x2x2mm) were dissociated into single cells using Tumor Dissociation kit (#130-095-929, Miltenyi Biotec). For each sample, enzyme mix was prepared in 5ml of RPMI (without FBS) containing 40µL of Enzyme H, 20µL of Enzyme R, and 5µL of Enzyme A in a tube. Tissue fragments were added and dissociated using gentleMACS Octo Dissociator (130-095-937, Miltenyi Biotec) using in-built programs. Post dissociation, wash buffer containing FBS was added and filtered using 70µm filter. The cells were washed in PBS.

**Flow Staining and Acquisition:** The cells were first stained with Live/Dead dye in PBS, followed by Fc blocking in FACS buffer (2% FBS in PBS). Then the cells were stained with the surface marker cocktail. Post that the cells were fixed and permeabilized and stained with intracellular marker cocktail. Data was acquired in BD LSR Fortessa using appropriate compensation controls.

## Study Workflow




## Flow Cytometry Based Assay Design

Panel: 11color 13 marker

ANTIBODY	FLUROCHROME	CLONE
CD45	PERCP	2D1
CD3	BV510	OKT3
CD4	FITC	SK3
CD8	APC H7	SK1
CD14	PE CY7	M5E2
CD56	BV711	NCAM.16
CD66b	PE	G10F5
PD-1	BV421	EH12.2H7
CD19	FITC	HIB19
HLA-DR	BV650	L243
FOX P3	APC	236A/E7
EpCAM	PE	EBA1
CYTOKERATIN (7/8, CK)	PE	CAM5.2
LIVE/DEAD™ Fixable Blue	indo-V	NA



## Flow Gating Strategy




## Analysis:

- All gating was performed using FMO controls.
- The flowcytometry analysis was performed using FlowJo
- For all other analysis GraphPad Prism was used


## Tumor Content in tissues evaluation: Pathology scoring vs Flow cytometry determination using EpCAM and CK




## Comparison of immune cells in matched PBMC and TILs of High Tumor Containing Cohort



## Infiltrated immune cells in High vs Low Tumor Containing cohorts:



## Comparison of TILs in CaBR and HNSCC



## Conclusion:

The results shows significantly higher Treg and exhausted CD8 T-cells in the TME versus the peripheral blood. Additionally, B-cells and NK-cells were observed in reduced prevalence in the TME. Interestingly, samples with higher tumor burden had elevated CD8 T-cells as well as Tregs, with lower effector CD4. Finally, when comparing Breast and HNSCC cancers TILs, there was a significant difference in total T-cell and Myeloid subset frequencies. With a higher proportion of Myeloid population in HNSCC than CaBR. These finding highlight the need for direct measure of the tumor immune status and the caution needed when assessing the peripheral compartment and applying observations to the tumor microenvironment.

## References:

- Marshall, Henry, et al. "Immuno-oncology: emerging targets and combination therapies." *Frontiers in oncology* 8 (2018): 315.
- Li, Xiaotong, et al. "Immune profiling of pre-and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial." *Journal for immunotherapy of cancer* 7.1 (2019): 88.
- Binnewies, Mikhail, et al. "Understanding the tumor immune microenvironment (TIME) for effective therapy." *Nature medicine* 24.5 (2018): 541-550.

## Acknowledgement:

We acknowledge the cancer biology team and the tissue sourcing team for their effort.

